Aarti Pharmalabs Limited — Investor Meet, 04-11-2024: Analysts/Institutional Investor Meet/Con. Call Updates

Aarti Pharmalabs Limited shared a transcript from its Q2/H1 FY25 earnings call, highlighting a 13% year-on-year revenue increase to ₹1014 crore and a PAT rise of 11% to ₹110 crore. The Xanthine segment contributed 45% to turnover, while API Intermediates comprised 51%. CDMO/CMO made up 3%. Key expansions were discussed, including increased Xanthine capacity and a new solar energy project. The company maintains a 10%-12% EBITDA growth outlook for FY25 and anticipates long-term opportunities from recent investments.